Identification of Predictors for Optimizing Clinical Outcomes After Allogeneic Stem Cell Transplantation

Allogeneic stem cell transplantation (allo-SCT) is often the only  curative treatment option for malignant and non-malignant hematological stem cell disorders. However, allo-SCT can associate with serious complications, including graft failure, disease relapse, and graft-versus-host disease (GVHD), potentially leading to life-threatening conditions or long-term morbidity. The aim of this project is to identify predictors for optimizing clinical outcomes of allo-SCT.

In the UMCU a novel allo-SCT platform has been developed based on ex vivo depletion of αβ-T cells of the allograft. Stuut et al. have shown that with this approach the proportion of patients surviving without GVHD and without relapse is increasing. This project will start by linking these clinical data to pharmacological data, patient-reported outcomes and to immunological parameters.

We hypothesize that a ‘one size does not fit all’ approach will not be sufficient, and that by establishing a comprehensive dataset of our parameters of interest, we can identify disease- and patient-specific opportunities or challenges. This will allow us to tailor allo-SCT outcomes at the patient level. Ultimately, this research could contribute to the development of more effective treatment protocols and reduce the burden of post-transplant complications.

Contact 
Pleun Schonewille